Supporting patients is always at the forefront of our work to translate our science into innovative treatment options. As Tony Rosenberg shares, this dedication to patients was evident from day one.? ? Learn more about our patient commitment:?https://bit.ly/3ZmbAKG #TogetherWeDiscover
argenx
生物技术研究
Boston，MA 72,202 位关注者
United in our commitment to improve the lives of patients
关于我们
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
- 网站
-
https://www.argenx.com
argenx的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Boston，MA
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Oncology、Autoimmune diseases、Rare Diseases、Antibody based medicines、Immunotherapy、Myasthenia Gravis、Immunology、Pemphigus Vulgaris、Immune Thrombocytopenia、Acute Myeloid Leukemia 、high-risk myelodysplastic syndromes和chronic inflammatory demyelinating polyneuropathy
地点
argenx员工
动态
-
Driving innovation in autoimmune disease treatment begins with deepening our understanding of conditions through meaningful connections with the patient community. Bilal's journey with thyroid eye disease (TED) highlights the value of patient?insights in advancing care and research. To learn more about Bilal's experience, read his story below??? #TogetherWeDiscover
I am a registered Diverse Supplier helping biotech, pharma, and medical devices companies bring their products to market and patients through regulatory submissions and medical communications.
It's been 2 years since my eye decompression surgery for my thyroid eye disease. It's been a long and testing road, but I am on it, with no turning back. Here is an article sharing my journey so far ???? #TED #thyroideyedisease #eyedecompressionsurgery #orbitaldecompressionsurgery #NHS #nationalhealthservice
-
We’re excited to announce a partnership with?Steritas to advance the evidence supporting novel steroid-sparing therapeutics across our immunology development programs.? ? We look forward to collaborating with Steritas to support the development of innovative steroid-sparing treatments for autoimmune diseases. Learn more:?https://bit.ly/4eMvvqG ? #TogetherWeDiscover?
-
Today we announced the decision to continue the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis) in each of the three myositis subtypes.? ? We are advancing our understanding of the pathophysiology of myositis, further establishing the causal role of IgG antibodies in the disease. Precision therapies now take this understanding one step further.? ? Learn more: https://bit.ly/4eKfiCd ? #TogetherWeDiscover?
-
-
At argenx, embracing a growth mindset drives both career advancement and patient impact. Our colleagues share how their motivation to seize professional growth opportunities stems from their passion for supporting patients. How has adopting a growth mindset helped you make a positive impact on patient care? Share below ?? #TogetherWeDiscover
-
Our Immunology Innovation Program (IIP) allows us to partner with leaders in disease biology. Associate Director of Strategic Alliances?Ruani Fernando harnesses her passion for collaboration into identifying IIP partners with transformative scientific discoveries. Discover more about the IIP and our partners:?https://bit.ly/3O4eOw9 #TogetherWeDiscover?
-
-
We’re proud to join?Making The Most of Now and?Clive Phillips to raise awareness of multifocal motor neuropathy (MMN) through the Tour de MMN in 2025. The Tour de MMN raises awareness and funding for MMN research by GBS|CIDP Foundation International through a cycling ride across France. It’s an honor to support this initiative to bring hope, support, and resources to the MMN community. #TogetherWeDiscover #TourdeMMN?
Tour de MMN 2025 Lead Sponsor Announcement The Tour de MMN aims to increase awareness of MMN, connect the MMN community and raise funds for the GBS|CIDP Foundation International MMN research fund. To achieve these goals we will not just be riding around France next year, but will be organising MMN community events before and during the ride. We will also be filming a documentary to help us continue our work well beyond the finish line in Paris on 23 June. To help us achieve our goals we are incredibly excited to announce that argenx have agreed to come on board as lead sponsor of the Tour de MMN. Like us argenx are committed to furthering understanding of auto immune diseases like MMN and to improving the lives of those affected by them. With their headquarters in Ghent, a real cycling city, they also share our love of the bike and its power to bring people together and improve health outcomes. We are truly excited to have argenx collaborating with us on this project. #TogetherWeDiscover Riding with #multifocalmotorneuropathy #rideformmn #raredisease #TourdeMMN
-
-
At argenx, innovation is at the center of our work to transform scientific discovery into transformative treatments. We're proud of the progress we've made thus far and remain committed to expanding our global patient reach. #TogetherWeDiscover
In the fast-paced world of biotech, innovation is not just a competitive edge – it’s a necessity for companies aiming to pioneer revolutionary treatments and therapies. For this article in BiotechNEWS & Life Sciences we zoom in on Belgium’s biotech success story argenx and spoke with Vice President Corporate Development & Strategy Arjen Lemmen, about argenx’ journey, strategy, company mission and the importance of partnerships. ? Read the full article on the website and subscribe to receive the magazine by mail or digitally. https://lnkd.in/e_zcZJZh ? Follow us on LinkedIn to stay up to date with interesting sector news and posts. ? BiotechNEWS & Life Sciences is the magazine that provides the Dutch & Belgium Life Sciences sector with sector news and updates on the latest developments and interesting trends. The next edition will be published in the end of November. For advertising and publishing opportunities contact us at [email protected].?
-
-
More than 65 million people in the U.S.?provide care for a family member during any given year. Tony, a myasthenia gravis (MG) patient, and his wife Catherine highlight the immeasurable difference caregivers make in their loved ones’ journey.? ? This #NationalFamilyCaregiversMonth, we want to celebrate and thank family caregivers for all they do for those they support. Their unwavering dedication is truly inspiring.? ? #TogetherWeDiscover?
National Caregivers Month
-
Our third-quarter earnings report is now available. This quarter we: ???Increased our patient impact, expanding our gMG footprint and delivering innovation to CIDP patients ???Advanced Vision 2030, investing in our continuous pipeline of differentiated antibody candidates, with the goal of reaching 50,000 patients and 10 labeled indications by 2030 ???Further invested in our Immunology Innovation Program (IIP) with the nomination of four new pipeline candidates to drive long-term, sustainable growth Read the full Q3 earnings report: https://bit.ly/4f76Zl0 #TogetherWeDiscover
-